← brief for 2026-08-12 · Slowing decline

Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.

Article No results yet Peer reviewed

Key takeaways

This review discusses using GLP-1 and SGLT2 medicines together to protect the heart in high-risk patients. Both drug types are also used to protect the kidneys. It is a review, so it reports no new data.

Who did this work

Mohanty SS · Selvammathy RR · Ahad HA · Kumar ES

Source

Article · PubMed, the drug frontier · 2026 Jul 1
https://pubmed.ncbi.nlm.nih.gov/42583965/